Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Assets (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Assets for 14 consecutive years, with $836.7 million as the latest value for Q4 2025.

  • Quarterly Assets changed 0.46% to $836.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $836.7 million through Dec 2025, changed 0.46% year-over-year, with the annual reading at $836.7 million for FY2025, 0.46% changed from the prior year.
  • Assets hit $836.7 million in Q4 2025 for Corcept Therapeutics, up from $823.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $846.5 million in Q1 2025 to a low of $423.8 million in Q4 2021.
  • Historically, Assets has averaged $643.6 million across 5 years, with a median of $605.9 million in 2023.
  • Biggest five-year swings in Assets: fell 25.88% in 2021 and later skyrocketed 37.68% in 2022.
  • Year by year, Assets stood at $423.8 million in 2021, then soared by 37.68% to $583.4 million in 2022, then grew by 6.53% to $621.5 million in 2023, then skyrocketed by 35.24% to $840.6 million in 2024, then dropped by 0.46% to $836.7 million in 2025.
  • Business Quant data shows Assets for CORT at $836.7 million in Q4 2025, $823.6 million in Q3 2025, and $801.7 million in Q2 2025.